SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Schwarz Kathrin)
 

Sökning: WFRF:(Schwarz Kathrin) > A targeted mass spe...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005520naa a2200457 4500
001oai:lup.lub.lu.se:275edae5-a731-4812-a394-5d008a254701
003SwePub
008190722s2019 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/275edae5-a731-4812-a394-5d008a2547012 URI
0247 a https://doi.org/10.1074/mcp.RA118.0012212 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Huttenhain, Ruthu ETH Zürich4 aut
2451 0a A targeted mass spectrometry strategy for developing proteomic biomarkers : a case study of epithelial ovarian cancer
264 1c 2019
520 a Protein biomarkers for epithelial ovarian cancer are critical for the early detection of the cancer to improve patient prognosis and for the clinical management of the disease to monitor treatment response and to detect recurrences. Unfortunately, the discovery of protein biomarkers is hampered by the limited availability of reliable and sensitive assays needed for the reproducible quantification of proteins in complex biological matrices such as blood plasma. In recent years, targeted mass spectrometry, exemplified by Selected Reaction Monitoring (SRM) has emerged as a method, capable of overcoming this limitation. Here, we present a comprehensive SRM-based strategy for developing plasma-based protein biomarkers for epithelial ovarian cancer and illustrate how the SRM platform, when combined with rigorous experimental design and statistical analysis, can result in detection of predictive analytes.Our biomarker development strategy first involved a discovery-driven proteomic effort to derive potential N-glycoprotein biomarker candidates for plasma-based detection of human ovarian cancer from a genetically engineered mouse model of endometrioid ovarian cancer, which accurately recapitulates the human disease. Next, 65 candidate markers selected from proteins of different abundance in the discovery dataset were reproducibly quantified with SRM assays across a large cohort of over 200 plasma samples from ovarian cancer patients and healthy controls. Finally, these measurements were used to derive a 5-protein signature for distinguishing individuals with epithelial ovarian cancer from healthy controls. The sensitivity of the candidate biomarker signature in combination with CA125 ELISA-based measurements currently used in clinic, exceeded that of CA125 ELISA-based measurements alone. The SRM-based strategy in this study is broadly applicable. It can be used in any study that requires accurate and reproducible quantification of selected proteins in a high-throughput and multiplexed fashion.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Choi, Meenau Northeastern University4 aut
7001 a Martin de la Fuente, Laurau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröst- och ovarialcancer,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breast and Ovarian Cancer Genomics,Lund University Research Groups4 aut0 (Swepub:lu)med-lrm
7001 a Oehl, Kathrinu University Hospital of Zurich4 aut
7001 a Chang, Ching-Yunu Purdue University4 aut
7001 a Zimmermann, Anne-Kathrinu University Hospital of Zurich4 aut
7001 a Malander, Susanneu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-sma
7001 a Olsson, Hakanu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Melanoma Study Group,Lund University Research Groups4 aut0 (Swepub:lu)onk-hol
7001 a Surinova, Silviau ETH Zürich4 aut
7001 a Clough, Timothyu Purdue University4 aut
7001 a Heinzelmann-Schwarz, Violau University Hospital Basel4 aut
7001 a Wild, Peter Ju University Hospital Frankfurt4 aut
7001 a Dinulescu, Danielau Harvard Medical School4 aut
7001 a Niméus, Emmau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,Bröstcancer Proteogenomik,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breast Cancer Surgery,Lund University Research Groups,Breast cancer Proteogenomics4 aut0 (Swepub:lu)onk-ens
7001 a Vitek, Olgau Northeastern University4 aut
7001 a Aebersold, Ruediu ETH Zürich4 aut
7102 a ETH Zürichb Northeastern University4 org
7730 t Molecular and Cellular Proteomicsg 18:9, s. 1836-1850q 18:9<1836-1850x 1535-9484
8564 u http://dx.doi.org/10.1074/mcp.RA118.001221y FULLTEXT
8564 8u https://lup.lub.lu.se/record/275edae5-a731-4812-a394-5d008a254701
8564 8u https://doi.org/10.1074/mcp.RA118.001221

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy